CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma .
http://ift.tt/1eEpGcz
http://ift.tt/1eEpGcz
No comments:
Post a Comment